Novartis signed an agreement with CELLforCURE to produce innovative cancer treatments known as CAR-T therapies (chimeric antigen receptor T-cells) at the bioproduction site based in Les Ulis (Essonne).
SK Holdings, the parent company of South Korea’s third-largest conglomerate SK Group, announced that it has acquired a 100 percent stake in AMPAC Fine Chemicals, a US-based contract manufacturer of APIs.
Fermion Oy, a privately held Finnish manufacturer of active pharmaceutical ingredients (APIs), has reached a significant milestone in its investment project by entering the commissioning phase of its new plant in Hanko (Finland).
A relevant draft order on additional preferences for manufacturers is being prepared for state registration in the Ministry of Justice, announced the press service of the Russian Ministry of Industry and Trade.
CASI Pharmaceuticals, a US-based biopharmaceutical company, will expand its presence in China by entering into a long-term manufacturing agreement with China’s Yiling Wanzhou International Pharmaceutical Co. Ltd
CellGenix, a global manufacturing leader of GMP-grade raw materials for cell therapy, gene therapy and tissue-engineered products, successfully completed the first phase of its headquarters’ expansion.
NPO Biomed, the largest developer and manufacturer of immunobiological products in the Perm Krai, an affiliate of NPO Microgen of Nacimbio Holding Company, part of Rostec Corporation, marked its 120th anniversary.